NCT03740997View on ClinicalTrials.gov

Study to Determine Safety and Dosage of OPTISON in Pediatric Participants

PHASE4CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Transthoracic EchocardiographySuspected or Known Structural or Functional Cardiac Abnormality
Interventions
DRUG

Optison

Optison is administered intravenously

Trial Locations (8)

11042

Cohen Children's Medical Center of New York, Lake Success

21287

Johns Hopkins University School of Medicine, Baltimore

30912

MCG Health, Inc., Augusta

44195

Cleveland Clinic Foundation, Cleveland

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

77030

Baylor College of Medicine, Houston

85016

Phoenix Children's Hospital, Phoenix

90027

Children's Hospital Los Angeles, Los Angeles

Sponsors

Lead Sponsor

GE Healthcare
All Listed Sponsors
collaborator

Laboratory Corporation of America

INDUSTRY

lead

GE Healthcare

INDUSTRY

NCT03740997 - Study to Determine Safety and Dosage of OPTISON in Pediatric Participants | Biotech Hunter | Biotech Hunter